Compare Adaptive Biotechnologies Corp (ADPT) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Canadian National Railway Co. — how do they compare? Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B), while Canadian National Railway Co. trades at $126.36 (market cap $76.28B). The key difference: Canadian National Railway Co. is far larger — about 18.9× Adaptive Biotechnologies Corp's market cap, and Canadian National Railway Co. pays a 2.06% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CNI | |
|---|---|---|
Market Cap | $4.04B | $76.28B |
Sector | Health | Industrials |
52-Week High | $25.45 | $130.58 |
52-Week Low | $12.30 | $90.91 |
Enterprise Value | $4.10B | $92.31B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
CNI trades at $126.32, up 0.94% today, with a neutral technical signal and bullish moving average trend. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.50 versus $1.39 expected, and raised full-year guidance. Key financials show a P/E of 22.62, net income margin of 26.92%, and ROE of 22.02%, supported by record grain movements in the 2025-26 crop year.
Outlook is positive due to operational excellence and volume growth, but valuation appears stretched with a consensus price target of $152.38. Risks include competitive pressures and macroeconomic volatility, while institutional sentiment leans neutral with 60.79% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
